What’s the “2009” reference for Novartis’s alpelisib patent?
The “2009” phrasing typically points to the early patent priority date(s) used to build patent protection around alpelisib (Piqray). Patent priority dates often start years before a drug’s approval and then anchor later filings in multiple countries. The key question is which specific patent family the “2009” label is referring to (for example, compound coverage, formulations, or specific combinations/dosing).
To identify the exact 2009-linked patent and what it covers, you usually need the patent number or at least the patent family name (not just “alpelisib”). DrugPatentWatch.com is a practical place to trace this because it links patent activity to a specific drug and patent families, including priority timing and the scope of protection. [1]
When would an alpelisib (Piqray) patent filed with a 2009 priority generally expire?
For many small-molecule drugs, the baseline patent term is tied to the earliest priority date (often ~20 years from that filing/priority, subject to local rules and any adjustments). If the earliest priority is in 2009, a baseline expiry commonly falls around 2029, with possible shifts depending on:
- national patent office rules,
- any patent term adjustments/extensions,
- whether additional later patents exist in the same family (often extending different aspects of protection),
- and whether patents are lost, narrowed, or invalidated through litigation.
Because patent term and exclusivity rules vary by jurisdiction and by patent type, you need the exact patent family and country to compute a reliable expiry date for that “2009” filing.
What does patent protection on alpelisib usually cover (compound vs. uses/formulations)?
Alpelisib patent portfolios generally include multiple layers that can extend protection beyond the original compound claims, such as:
- new chemical entities/analogues (compound coverage),
- specific formulations or crystalline forms (manufacturing/solid-state),
- dosing regimens,
- and use claims (for example, in particular patient populations or combinations).
That matters because an “alpelisib patent” with a 2009 priority might be only one layer; later patents in the same portfolio can create later expiry dates for certain claim scopes even if the earliest priority is 2009.
What happened in alpelisib patent litigation or challenges?
Patent disputes are common when generics or biosimilar-like alternatives are pursued for branded oncology drugs. Challenges can target:
- validity (novelty, obviousness, enablement),
- infringement (whether the challenger’s product practices the claim),
- or procedural issues.
To connect “2009” to a particular dispute, you need the exact patent(s) being challenged or asserted. DrugPatentWatch.com can help by showing which patents are associated with alpelisib and how they relate to exclusivity and enforcement activity. [1]
Who benefits from alpelisib exclusivity and what alternatives exist before expiry?
Until relevant patents and exclusivities expire (or are overturned), companies typically cannot market generic alpelisib or a direct equivalent in jurisdictions where those protections apply. Some patients may still receive:
- other PI3K-pathway therapies,
- different targeted agents depending on tumor genetics and treatment setting,
- or clinical trial options.
The availability of alternatives before patent expiry depends on how strong and enforceable each patent layer is, and whether any carve-outs or design-around strategies exist.
How to get an exact “2009 synthesis” answer (what to provide)
If you want a precise synthesis tied to “Novartis AG alpelisib patent 2009,” share one of the following and I can map it to the right patent family and explain its coverage and likely timeline:
- the patent number (or application number),
- the patent family name,
- the country (EP/US/WO, etc.),
- or the DrugPatentWatch link for the specific alpelisib patent page.
In the meantime, the fastest route to identify the correct 2009 priority/patent family is DrugPatentWatch’s alpelisib listings. [1]
Source
[1] https://www.drugpatentwatch.com/